ISR News and Press, IsoRay Inc. From 11/10/21

IsoRay (NYSE:ISR): FQ1 GAAP EPS of -$0.02 misses by $0.01. Revenue of $2.56M (+7.6% Y/Y) beats by $0.06M. Press Release Isoray CEO Lori Woods said, “We are encouraged by the prospects for our core prostate brachytherapy business which grew year over year again this quarter. A...

Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed...

IsoRay (NYSE:ISR) is scheduled to announce Q1 earnings results on Wednesday, November 10th, after market close. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $2.5M For further details see: IsoRay Q1 2022 Earnings Preview

OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...

RICHLAND, Wash. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial ...

RICHLAND, Wash., Sept. 28, 2021 (GLOBE NEWSWIRE) -- The American Brachytherapy Society (ABS) has recognized Isoray ’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has...

IsoRay, Inc. (ISR) Q4 2021 Earnings Conference Call September 21, 2021, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Frank Takkinen - Lake Street Tim Chiang - Northland Capital Mike Ott - Oppenheimer Presentation Operator G...

RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray , Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, will host a rescheduled conference call to discuss its financial results for ...

Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options ...

ACB, ADBE, FDX, ISR, SFIX For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close